Plain-English translation of NCT07483450 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing , a medication designed to help people with two types of multiple sclerosis: relapsing MS (where symptoms come and go) and primary progressive MS (where symptoms gradually worsen over time). Researchers want to understand how well this medication works and how safe it is for Chinese patients. The study will also look at how the medication behaves in the body and its effects on the immune system.
Multiple sclerosis is a serious condition where the immune system attacks nerve fibers, causing disability over time. While this medication has been used in other countries, researchers need to study how it works specifically in Chinese patients to make sure it is both effective and safe for this population.
If you join this study, you will receive the medication through an IV infusion into your arm. For the first cycle (first 24 weeks), you will receive two infusions, one on day 1 and another on day 15. After that, you will receive one infusion every 24 weeks. Researchers will monitor your health with regular visits, blood tests, and MRI scans to see how well the treatment is working and to watch for any side effects. The study is designed specifically for patients in China and aims to enroll about 60 participants total across both types of MS.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China